Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Lantern Pharma (NASDAQ: LTRN) Brings Open-Medicine AI Roadmap to September 23 Webinar

Lantern Pharma is a Pharmaceuticals: Major company. Lantern Pharma (NASDAQ: LTRN) presented its Open-Medicine AI platform roadmap to investors on September 23, 2026. The session addressed the platform’s development plans, customer needs, commercial model, benchmarks andPartnershipdiscussions.

Vinay Lochav | 23 September 2026

MeiraGTx (NASDAQ: MGTX) Appoints Alan M. Sebulsky to Board Through 2028

MeiraGTx Holdings plc (NASDAQ: MGTX) is a biotechnology company. Alan M. Sebulsky joined its board effective September 23, with his term extending until the 2028 annual meeting of shareholders. He will also serve on the Science and Technology Committee.

Vinay Lochav | 23 September 2026

Moleculin Biotech (NASDAQ: MBRX) Secures Mexican Patent, Issues 888,400 Shares

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a Pharmaceuticals: Major company. It secured Mexican Patent No. 436,849 for its lung-targeted liposomal Annamycin technology, while its ATM offering produced $0.48 million in aggregate gross proceeds from September share issuances. The patent remains effective until November 23, …

Vinay Lochav | 23 September 2026

ProQR (NASDAQ: PRQR) Adds AI Expertise as AX-0811 Data Nears in 2027

ProQR Therapeutics N.V. (NASDAQ: PRQR) is a Pharmaceuticals: Major company. Chris Hart has been appointed chief data and AI officer, while Thomas Wolf is set to join the Board of Directors as a strategic AI advisor.

Vinay Lochav | 23 September 2026

KAMADA LTD (NASDAQ: KMDA) Awards 60,000 Derivative Securities to VP Quality

KAMADA LTD (NASDAQ: KMDA) is a biotechnology company. The transaction left Brenner with 60,000 derivative securities in KAMADA LTD. KMDA is the company’s trading symbol on Nasdaq. The 60,000 securities awarded in the transaction correspond to about 100.0% of Brenner Yael’s resulting total of …

Vinay Lochav | 23 September 2026

Cardiol Therapeutics (NASDAQ: CRDL) Expands MAVERIC Trial, Targets Mid-2027 Results

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a biotechnology company. It has reached the enrollment goal for its Phase III MAVERIC trial and is expanding the study, with topline results now anticipated in mid-2027.

Vinay Lochav | 23 September 2026

Clearmind Medicine (NASDAQ: CMND) Expands U.S. Patent Portfolio With Psychedelic Combinations

The company expanded its U.S. intellectual-property position by publishing patent applications covering combinations of LSD, ketamine and ibogaine with N-acylethanolamines. The applications address potential therapeutic uses in mental health disorders, pain and substance use disorders.

Vinay Lochav | 23 September 2026

Corcept (NASDAQ: CORT) Names Justin Gunn to Lead Endocrinology From October 1

Corcept Therapeutics Inc (NASDAQ: CORT) is a major pharmaceuticals company. Sean Maduck will leave his position as President of Corcept’s Endocrinology division on October 1, 2026, and Justin Gunn will take over the role. Maduck will remain involved as a senior commercial adviser under …

Vinay Lochav | 23 September 2026

CTT Pharmaceutical Holdings Adds Karen Larson as Independent Board Member

CTT Pharmaceutical Holdings, Inc. (OTC: CTTH) is a Pharmaceuticals: Major company. The company has added Karen Larson as an Independent Board Member. Larson is a Certified Financial Planner (CFP) with experience in running companies, along with professional ties to analytical reporting, investment banking and …

Vinay Lochav | 23 September 2026

Glucotrack (NASDAQ: GCTK) Files Update on LT-100 and ai² Platform

Glucotrack is advancing LT-100 while its ai² platform applies pharmaceuticalDue Diligenceacross more than 12,000 late-stage programs. The priorities matter to investors because the update links near-term clinical development with a stated model of discovering, advancing and monetizing therapeutic assets, while Glucotrack Technologies continues its …

Vinay Lochav | 23 September 2026
Support

Hi! How can we help you today?

Loading…